文献速递乳腺乳腺X线MR

预测新辅助化疗反应:在对比增强能谱乳腺摄影中加入数字乳腺断层摄影能否提高准确性?与乳腺MRI的比较

Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI.
PubMed 文献 · Br J Radiol · 2023-06-29

本研究纳入接受新辅助化疗的乳腺癌患者,于化疗后行对比增强能谱乳腺摄影联合数字乳腺断层摄影及乳腺MRI检查,并与病理标本对照。对比增强能谱乳腺摄影强化预测病理完全缓解的准确性为81.3%,敏感度100%,特异度57.1%;MRI准确性62.5%,敏感度44.4%,特异度85.7%。加入数字乳腺断层摄影未提高预测准确性。

要点

  • 对比增强能谱乳腺摄影强化预测病理完全缓解的准确性为81.3%,敏感度100%,特异度57.1%。
  • MRI预测病理完全缓解的准确性为62.5%,敏感度44.4%,特异度85.7%。
  • 对比增强能谱乳腺摄影强化与浸润性肿瘤大小的符合系数为0.70,MRI为0.66。

核心结论

  • 对比增强能谱乳腺摄影在预测新辅助化疗后残留病变方面与MRI相似。
  • 仅强化范围与浸润性病变的符合性最佳;纳入残留微钙化可提高与导管原位癌的符合性。
  • 在对比增强能谱乳腺摄影中加入数字乳腺断层摄影未提高预测准确性。

研究设计与样本

  • 研究纳入接受新辅助化疗的乳腺癌女性,化疗后行对比增强能谱乳腺摄影联合数字乳腺断层摄影及乳腺MRI检查,并与病理标本对照。
  • 共纳入14例患者的16个癌灶,其中10个达到病理完全缓解。

诊断标准与关键数值

  • 对比增强能谱乳腺摄影强化预测病理完全缓解:准确性81.3%,敏感度100%,特异度57.1%。
  • MRI预测病理完全缓解:准确性62.5%,敏感度44.4%,特异度85.7%。
  • 对比增强能谱乳腺摄影强化与浸润性肿瘤大小的符合系数为0.70,MRI为0.66。
  • MRI与整体肿瘤大小的符合系数为0.86,对比增强能谱乳腺摄影联合微钙化为0.69。
  • 对比增强能谱乳腺摄影联合数字乳腺断层摄影低估残留病变大小,MRI高估,但差异无统计学意义(p>0.05)。

临床应用与阅片要点

  • 对比增强能谱乳腺摄影强化可用于预测新辅助化疗后病理完全缓解,其敏感度100%、特异度57.1%。
  • 评估残留浸润性病变大小时,对比增强能谱乳腺摄影强化的符合系数为0.70,高于MRI的0.66。
  • 评估残留导管原位癌时,对比增强能谱乳腺摄影联合微钙化的符合系数为0.69,高于MRI的0.86不适用。
  • 在对比增强能谱乳腺摄影中加入数字乳腺断层摄影未提高预测病理完全缓解或残留病变大小的准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Image monitoring is essential to monitor response to neoadjuvant chemotherapy (NACT). Whilst breast MRI is the gold-standard technique, evidence suggests contrast-enhanced spectral mammography (CESM) is comparable. We investigate whether the addition of digital breast tomosynthesis (DBT) to CESM increases the accuracy of response prediction.

METHODS: Women receiving NACT for breast cancer were included. Imaging with CESM+DBT and MRI was performed post-NACT. Imaging appearance was compared with pathological specimens. Accuracy for predicting pathological complete response (pCR) and concordance with size of residual disease was calculated.

RESULTS: Sixteen cancers in 14 patients were included, 10 demonstrated pCR. Greatest accuracy for predicting pCR was with CESM enhancement (accuracy: 81.3%, sensitivity: 100%, specificity: 57.1%), followed by MRI (accuracy: 62.5%, sensitivity: 44.4%, specificity: 85.7%). Concordance with invasive tumour size was greater for CESM enhancement than MRI, concordance-coefficients 0.70 vs 0.66 respectively. MRI demonstrated greatest concordance with whole tumour size followed by CESM+microcalcification, concordance coefficients 0.86 vs 0.69. DBT did not improve accuracy for prediction of pCR or residual disease size. CESM+DBT underestimated size of residual disease, MRI overestimated but no significant differences were seen (p>0.05).

CONCLUSIONS: CESM is similar to MRI for predicting residual disease post-NACT. Size of enhancement alone demonstrates best concordance with invasive disease. Inclusion of residual microcalcification improves concordance with ductal carcinoma in situ. The addition of DBT to CESM does not improve accuracy.

ADVANCES IN KNOWLEDGE: The addition ofDBT to CESM does not improve NACT response prediction. CESM enhancement has greatest accuracy for residual invasive disease, CESM+calcification has greater accuracy for residual in situ disease.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Savaridas, Vinnicombe, Warwick, et al. Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI. Br J Radiol. 2023. PMID: 37399083. doi:10.1259/bjr.20220921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。